Accelerate your precision oncology drug development
Incorporate real-world clinical genomic insights to improve your biomarker-driven clinical trial design, with potential impact on inclusion and exclusion criteria, endpoint selection, and stratification of treatment regimen. With data from over 175,000 patients, our GuardantINFORM™ real-world clinical-genomic platform is one of the largest of its kind. This robust dataset offers insights into anti-cancer therapy use in the clinic, tumor evolution, and treatment resistance throughout each patient’s treatment journey.
Utilize GuardantINFORM at all phases of drug development:
Targeted drug development
Identify, characterize, and prioritize patients with biomarker-defined cancers and in need of treatment options for potential new drug development indications and label expansions.
Clinical trial optimization
Incorporate real-world clinical-genomic data into clinical trial design, control arm simulation, clinical operations activities, and clinical development decision-making.
Post-marketing studies
Conduct health outcomes and safety studies of on- and off-label use of marketed therapies using real-world market insights and estimates of progression-free and overall survival in biomarker-defined cancers.
Our database by the numbers
Cancer types
Distinct cancer treatments
Distinct cancer-related procedures
Patients with >1 Guardant360 test
Patients with integrated clinical and molecular information
GuardantINFORM™ enables research on topics such as acquired resistance, the presence of specific alterations impacting the efficacy of a drug, and the impact of co-occurring biomarkers on clinical outcomes, across over 60+ cancer types.
Mapping the longitudinal patient journey with real-world evidence
The GuardantINFORM™ database reconstructs an mNSCLC patient journey and assesses real-world duration of first line aNSCLC targeted therapy following ctDNA biomarker identification. Source: Yu J, Marino E, Hanna D, et al. Real-world first line targeted therapy duration following ctDNA testing in advanced non small cell lung cancer. Journal of Thoracic Oncology. S689, MARCH 1, 2021
Calculating real-world outcomes
These GuardantINFORM™ data demonstrate outcomes for first line targeted aNSCLC treatment base using the Guardant360® test. These results show similar outcomes to tissue guided first line targeted therapy. Source: Yu J, Marino E, Hanna D, et al. Real-world first line targeted therapy duration following ctDNA testing in advanced non small cell lung cancer. Journal of Thoracic Oncology. S689, MARCH 1, 2021